As the ISS winds down, pharmaceutical work in orbit is moving from experiment to commercial production. Economic development organisations that still treat BioSpace as science tourism will miss the jobs and the capital.
The International Space Station has been a useful laboratory. It has not been a factory. That distinction is about to matter.
Drugmakers and the specialist firms that serve them are preparing for the next phase of pharmaceutical work in low Earth orbit. The science is familiar: microgravity can produce protein crystals and biological structures that are difficult or impossible to grow cleanly on the ground. What is new is the industrial posture. Private platforms, autonomous capsules and contracted programmes are replacing the scarcity of astronaut time and the queue for a berth on the ISS. The work is leaving the category of demonstration.
In the past fortnight the signal has been consistent. Executives at pharmaceutical and space firms told reporters they are laying ground for reliable, lower-cost production outside Earth’s gravity well, and they are talking to regulators about the rules that will govern medicines made in orbit. Varda has already flown multiple capsules and secured balance-sheet work from a listed biotech. BioOrbit raised a substantial seed round to industrialise crystallisation hardware the size of a microwave. Exobiosphere contracted mission management for an automated high-throughput screening platform intended for permanent station use. LambdaVision is aiming clinical trials for a retinal implant assembled in microgravity. These are not press releases about the wonder of space. They are statements about capacity, cadence and return logistics.
For economic development organisations the temptation is to celebrate the science. That would be a mistake. The prize is not the experiment. It is the companies, the customers and the places that can hold the terrestrial half of the system once the product has to leave the capsule and enter a regulated supply chain.
Microgravity manufacturing does not float free of the ground. It needs sterile fill-finish, cold chain, quality systems that a regulator will recognise, and a workforce that can run both the orbital interface and the terrestrial plant. It needs sites that can accept returned material without turning every recovery into a one-off adventure. It needs capital that understands dual timelines: the orbital campaign and the multi-year regulatory path that follows. Regions that already possess formulation strength, biologics manufacturing, or a serious medical-device base sit closer to this work than regions that only possess a university lab and a launch narrative.
The commercial shift is also a sovereignty and resilience question by another name. Allied health systems and defence medical logistics have an interest in formulations that are more stable, more portable, or manufacturable under conditions that terrestrial plants cannot easily match. That does not make every BioSpace project a defence project. It does mean that the industrial base which can support orbital pharmaceutical work will look a good deal like the industrial base that supports other high-reliability, high-regulation manufacturing. EDOs that already think in those terms will recognise the adjacency. Those that still organise around “space as experience” will not.
Location decisions will follow the same logic they always do once a technology leaves the grant phase. Buyers care about reliable access, predictable cost, and a counterpart who can deliver under a contract rather than a memorandum. Investors care about the same things, plus a path to scale that does not depend on a single station’s remaining life. The private stations and the capsule fleets are being built precisely because the ISS model cannot support that. Regions that can offer ground capacity, skills and a clear path to commercial partners will convert. Regions that offer only a soft-landing package and a photograph of a rocket will not.
None of this requires every place to chase a pad or a station module. Most of the payroll will sit in the industries a region already has: sterile manufacturing, advanced materials, instrumentation, logistics, regulatory know-how. BioSpace is an extension of life sciences and advanced manufacturing, not a replacement for them. The organisations that treat it as a separate theatre of activity will spend the next decade counting visitors. The ones that treat it as a conversion problem—companies that can sell, sites that can take the work, capital that will stay—will count jobs and investment.
The laboratory phase is ending. What follows is industrial.
LibLeo works with economic development organisations on frontier sectors. BioSpace is where life sciences and space meet the ground.